Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 3,872 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: FAST Clear all

Conditions: Prostate Neoplasms
Interventions: Stage 1 Group 1: abiraterone acetate, Stage 1 Group 2: abiraterone acetate, Stage 2: abiraterone acetate, Stage 3: abiraterone acetate, Stage 3: glucocorticoid, Stage 4: abiraterone acetate, Stage 4: glucocorticoid; Drug
Lead sponsor: Cougar Biotechnology, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metabolic Syndrome
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 35 Years to 50 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alzheimer's Disease
Interventions: florbetapir F 18; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 35 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: New Haven, Connecticut • Hallandale, Florida • West Palm Beach, Florida + 1 more

Conditions: Carnitine Transporter Deficiency
Interventions: Fasting blood and urine collection; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 2 Diabetes
Interventions: frequency of self monitoring blood glucose; Behavioral
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 79 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Right-To-Left Shunt
Interventions: Agitated Saline SoC, ASI-02; Drug
Lead sponsor: Agitated Solutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Chicago, Illinois • Rochester, Minnesota • Saint Cloud, Minnesota + 3 more

Conditions: Obesity & Overweight
Interventions: gut-brain axis (GLP-1)-activating food carbohydrate, starch-based placebo control (commercial maltodextrin); Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy Participants
Interventions: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Healthy
Interventions: Carvedilol Tablets 12.5 mg, Coreg® Tablets 12.5 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Type 1 Diabetes Mellitus
Interventions: SAR342434, Humalog, Insulin glargine HOE901; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 47
States / cities: Tucson, Arizona • Bell Gardens, California • Chula Vista, California + 36 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 50 Years and older
Enrollment: 9,651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 91
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Searcy, Arkansas + 79 more

Conditions: Asthma
Interventions: Hudson RCI® nebulizer, NebuTech® HDN® nebulizer, Albuterol; Device · Drug
Lead sponsor: Seton Healthcare Family; Other
Eligibility: 3 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Insulin Secretion
Interventions: Glucagon; Drug
Lead sponsor: David D'Alessio, M.D.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Age-related Macular Degeneration
Interventions: Diagnostics; Diagnostic Test
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 60 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Nicotine Use Disorder
Interventions: Realtime biofeedback using fMRI; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
Interventions: ASP015K; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Phenylketonurias
Interventions: PheCheck™, HPLC Amino Acid Analyzer, Dried Blood Spot Cards; Device · Diagnostic Test
Lead sponsor: Lumos Diagnostics; Industry
Eligibility: 10 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer
Interventions: Erlotinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Serious Mental Illness
Interventions: TAU, IMBED, Liaison; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CCX168; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: Maribavir; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Interventions: Burosumab; Drug
Lead sponsor: Laura Tosi; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Unstable Angina, Non-ST-Elevation Myocardial Infarction
Interventions: iSTAT point of care analyzer; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 1 Diabetes, De Novo Lipogenesis
Interventions: Oral Glucose Tolerance Test; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 22 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer

Early Vascular Wall Changes by Magnetic Resonance Imaging (MRI) in Metabolic Syndrome Versus Metabolically Normal Pre-Menopausal Women: A Pilot Study

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides

Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes

Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt

Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Comparison of Nebulizers in ED in Pediatric Asthma Patients

Glucagon Regulation of Glucose Metabolism

Global Atrophie Biomarker Evaluation Study (GABiE)

Real Time fMRI and Quitting Smoking

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

PheCheck Feasibility Study

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Treatment of Metabolic Syndrome in a Community Mental Health Center

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

Maribavir Food-Effect Study in Healthy Adults Participants

Burosumab for CSHS

Diagnosis and Treatment of Acute Coronary Syndrome in the ED & the Impact of Rapid Bedside cTnl on Outcome.

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes